How Does PT-141 (Bremelanotide) Work?

PT-141, known generically as bremelanotide, is a synthetic peptide that switches on melanocortin receptors, chiefly the MC4 receptor found on neurons in the brain. Instead of widening blood vessels the way sildenafil does, it appears to act on the brain circuits that generate sexual desire. As of September 2026, its only FDA-approved form is the bremelanotide autoinjector (1.75 mg, for premenopausal women with hypoactive sexual desire disorder, or HSDD). In the pivotal trials the benefit was real but modest: desire scores improved about 0.35 points more than placebo on a roughly 5-point scale, and 40% of women had nausea.

What PT-141 is and where it came from

PT-141 is the development code name that the company Palatin Technologies gave to bremelanotide. The two names refer to the same molecule. The FDA label describes it as a synthetic cyclic heptapeptide, meaning a ring-shaped chain of seven amino acids. It is a lab-made relative of a natural hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH.

You will see both names used. "Bremelanotide" is the name usually used for the FDA-approved autoinjector. "PT-141" is the name that stuck in the peptide and compounding world. If you are reading about one, you are reading about the other, although the product in your hand may be regulated very differently. More on that below.

The Melanotan II connection

The story starts with tanning research. Scientists at the University of Arizona designed long-acting versions of alpha-MSH, hoping to darken skin without sun exposure. One of these, a cyclic peptide called Melanotan II, turned out to have a second effect. In a 1996 pilot study in just 3 healthy men, it darkened skin and also produced spontaneous erections, and it went on to be tested as a treatment for erectile dysfunction.

That observation was tested formally. In a 1998 double-blind, placebo-controlled crossover study of 10 men with psychogenic erectile dysfunction (erection problems with no identified physical cause), 8 of the 10 developed clinically apparent erections after Melanotan II. Nausea, stretching, and yawning were the common side effects. A follow-up report from the same group covering 20 men found that increased sexual desire was reported after 68% of Melanotan II doses compared with 19% of placebo doses.

These were tiny studies, but they pointed at something new: a drug that seemed to initiate sexual response from the brain, without any sexual stimulation. A 2006 review by two of the original Arizona researchers describes PT-141 as a new Melanotan II analog, meaning a closely related molecule, that Palatin took into clinical trials for sexual dysfunction.

Why PT-141 is not the same thing as Melanotan II

Melanotan II is not an FDA-approved drug, and it has circulated as an unregulated tanning injection. The FDA discusses it among bulk substances that may present significant safety risks in compounding and notes that published case reports describe serious adverse events including melanoma, posterior reversible encephalopathy syndrome (a type of brain swelling), sympathomimetic toxidrome (a dangerous overstimulation state), and priapism (a prolonged erection that is a medical emergency). Bremelanotide is a different molecule with its own trial program and its own FDA-reviewed label. The family resemblance does explain one thing, though: both can darken skin.

How PT-141 works in the body

The melanocortin system in plain terms

Melanocortins are a family of natural signaling peptides that includes alpha-MSH. They act through five receptors, named MC1R through MC5R. A receptor is a protein on a cell's surface that works like a lock, and the peptide is the key. When the key fits, the cell changes what it is doing.

According to the approved product's prescribing information, bremelanotide is a nonselective melanocortin receptor agonist. "Agonist" means it activates the receptor. "Nonselective" means it activates several of them. The label gives the order of potency as MC1R, MC4R, MC3R, MC5R, then MC2R, and states that at therapeutic doses, binding to MC1R and MC4R matters most.

• MC4R is found on neurons in many areas of the central nervous system. This is the receptor linked to the drug's effect on desire.
• MC1R sits on melanocytes, the pigment-producing cells of the skin. The label states that binding here leads to melanin expression and increased pigmentation, which explains the skin-darkening side effect.

The brain pathway: MC4R, the hypothalamus, and dopamine

Here the evidence tiers matter, so they are laid out in order from weakest to strongest.

In rats. In a 2004 study published in the Proceedings of the National Academy of Sciences, PT-141 selectively increased solicitation behaviors in female rats, the behaviors researchers read as wanting sex, without changing reflexive mating postures, general movement, or the rewarding quality of sex. A later review of the rat work reported that the effect appeared when the drug was infused directly into the medial preoptic area, a small region of the hypothalamus that is critical for sexual motivation in many species, but not when it was infused into a neighboring region. The same review reported that injecting the drug under the skin activated the medial preoptic area and other hypothalamic and limbic regions, and that the drug may work by activating dopamine nerve terminals there. An earlier report from the developer found that systemic PT-141 activated neurons in the hypothalamus of rats and produced erections in rats and nonhuman primates.

In a small human imaging study. In 2022, researchers at Imperial College London published a randomized, double-blind, placebo-controlled crossover study in 31 premenopausal women with hypoactive sexual desire disorder. After a dose of an MC4R agonist (the paper's methods identify it as bremelanotide 1.75 mg by injection), the women reported higher sexual desire for up to 24 hours compared with placebo. On functional MRI, brain responses to erotic videos changed: activity rose in the cerebellum and supplementary motor area, fell in the secondary somatosensory cortex, and the connection between the amygdala and the insula strengthened. The authors interpreted this as less self-monitoring and greater sensitivity to erotic cues. This is one 31-person study, partly funded by the drug's then-marketer, so treat it as a mechanistic clue and not proof.

The working theory. A 2022 review of bremelanotide's neurobiology pulls these threads together. Sexual desire is thought to reflect a balance between excitatory signals in the brain (dopamine and the melanocortins among them) and inhibitory ones. The proposal, based mainly on the animal data, is that bremelanotide activates MC4 receptors on neurons in the medial preoptic area, which increases dopamine release and tips the balance toward excitation.

What the FDA label says about mechanism

The label states plainly that the mechanism by which bremelanotide improves HSDD in women is unknown. That sentence is worth holding onto when you read confident marketing copy. The dopamine story is a reasonable, animal-supported hypothesis. It has not been proven in people.

What happens after an injection

The label describes how the approved 1.75 mg dose moves through the body. After injection under the skin of the abdomen or thigh, essentially all of the dose is absorbed (bioavailability of about 100%). Blood levels peak at roughly 1 hour. The terminal half-life, the time it takes for blood levels to fall by half, averages about 2.7 hours, with a range of 1.9 to 4.0 hours. The peptide is broken down by ordinary hydrolysis of its amide bonds, and most of a labeled dose is recovered in urine (about 65%) and feces (about 23%).

The label directs use at least 45 minutes before anticipated sexual activity. It also admits two unknowns: the duration of effect after each dose is unknown, and the best timing window has not been fully characterized. In the 31-woman imaging study, the rise in desire was detectable for up to 24 hours, well after the drug itself would be mostly cleared. That fits a drug that triggers a downstream brain process instead of acting only while it is in the bloodstream.

How PT-141 differs from Viagra and other PDE5 inhibitors

People often call PT-141 "Viagra for the brain" or "female Viagra". Both labels mislead. The two drug types act at opposite ends of the sexual response.

Sildenafil (Viagra) and its cousins are PDE5 inhibitors. The Viagra label explains the mechanism: during sexual stimulation, nerves in the penis release nitric oxide, which raises levels of a messenger called cGMP, which relaxes smooth muscle and lets blood flow in. The PDE5 enzyme breaks cGMP down. Blocking PDE5 keeps cGMP around longer, so the erection is firmer and lasts longer. The label adds that sildenafil at recommended doses has no effect in the absence of sexual stimulation. In other words, it is plumbing support. It does nothing for desire.

Bremelanotide appears to work upstream, on motivation. In the early PT-141 studies, erections occurred in healthy male volunteers without any visual sexual stimulation, and Melanotan II did the same in men with erectile dysfunction, something a PDE5 inhibitor does not do. In women, the approved effect is on desire and on distress about low desire, not on genital blood flow. In fact, in an 18-woman lab study of an intranasal dose, vaginal blood flow measured during erotic videos did not change significantly compared with placebo, even though more women reported moderate or high desire.

One practical consequence of the different mechanisms: the two drug types are not interchangeable, and one cannot be assumed to fix the problem the other treats. Low desire and poor erectile blood flow are different problems that sometimes travel together.

FDA approval: what bremelanotide is approved for, and what it is not

The FDA approved the bremelanotide autoinjector in 2019. As of September 2026, the current label on the National Library of Medicine's DailyMed site, now under Cosette Pharmaceuticals, carries the same indication, dose, and limits as the original.

The indication is narrow. The approved product is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or interpersonal difficulty. "Acquired" means it developed in someone who previously had no problem with desire. "Generalized" means it happens regardless of the situation, type of stimulation, or partner. The low desire must not be better explained by another medical or psychiatric condition, by relationship problems, or by a medication or other substance.

The label then lists two limitations of use, quoted here in substance:

• It is not indicated for HSDD in postmenopausal women or in men.
• It is not indicated to enhance sexual performance.

The dosing limits on the label

These are the label's rules, stated for your understanding and not as personal dosing advice. The recommended dose is 1.75 mg injected under the skin of the abdomen or thigh with a prefilled autoinjector, as needed, at least 45 minutes before anticipated sexual activity. No more than one dose in 24 hours. More than 8 doses per month is not recommended, because frequent dosing raises the risk of skin darkening and increases the total time each month that blood pressure is elevated. The label also says to stop after 8 weeks if there is no improvement.

In the phase 3 trials, real-world use was well under those ceilings. Most women used the drug two to three times a month and no more than once a week.

What the RECONNECT trials actually found

Approval rested on RECONNECT, two identically designed phase 3 trials (studies 301 and 302) published in Obstetrics and Gynecology in 2019. Together they randomized 1,267 premenopausal women with HSDD, 1:1, to self-injected bremelanotide 1.75 mg or placebo, used as needed for 24 weeks. Almost all participants were at US sites, the mean age was 39, and about 86% were White. Both trials were funded by the drug's developers, which is normal for registration trials and worth knowing.

The two main results: desire and distress

There were two co-primary endpoints, both questionnaire-based. The first was the desire domain of the Female Sexual Function Index (FSFI), built from two questions about how often and how strongly you felt desire over the past 4 weeks. It is scored from 1.2 to 6, higher meaning more desire. The second was item 13 of the Female Sexual Distress Scale, a single question asking how often you felt bothered by low sexual desire, scored 0 (never) to 4 (always).

The figures in the table come from the FDA label. The published paper reports the model-estimated differences from placebo: for desire, 0.30 points in study 301 and 0.42 in study 302 (0.35 when pooled); for distress, 0.37 and 0.29 points lower (0.33 pooled). All were statistically significant. Differences were visible at week 4, the first time point measured, and held through week 24.

How big is that, really?

Statistically significant and large are different things. The paper reports a standardized effect size relative to placebo of 0.39 for desire and 0.27 for distress. By the convention the authors themselves cite, 0.2 is small, 0.5 is medium, and 0.8 is large. So the honest description is a small to moderate average effect. The authors note that this is in the same range reported for flibanserin, the other approved HSDD drug.

Averages hide spread. The median woman on placebo did not change at all on either scale, while the median woman on bremelanotide improved by 0.6 points on desire and a full point on distress. The label defines a meaningful response as a rise of at least 1.2 points in desire or a drop of at least 1 point in distress. When women were asked directly whether they benefited from the study drug, about 58% in each trial qualified as responders on bremelanotide compared with about 36% and 35% on placebo. That is roughly 22 to 23 more women in every 100 reporting a benefit because of the drug, alongside a large placebo response.

What did not improve: the number of satisfying sexual events

The key secondary endpoint was the number of satisfying sexual events. It did not move: the change from baseline was essentially zero in both groups in both trials. Bremelanotide changed how women felt about desire more than it changed how often satisfying sex happened. A post hoc analysis (one planned after the data were seen, and therefore weaker evidence) found that a larger share of sexual encounters were rated satisfying in the drug group.

Interestingly, the earlier phase 2b dose-finding trial, which randomized 397 women and analyzed 327, did find a difference on that measure: satisfying events per month rose by 0.7 with the two higher doses pooled, compared with 0.2 on placebo. The larger phase 3 trials did not reproduce it.

Dropouts, the open-label extension, and the critics

About 4 in 10 women assigned to bremelanotide left the trials early, far more than on placebo in study 301. Side effects drove much of that: 18% of drug-treated women stopped because of adverse reactions compared with 2% on placebo, with nausea alone accounting for 8%. High and unequal dropout makes any trial harder to interpret, and the label says so directly, presenting extra analyses that count everyone who quit as a non-responder. The authors report that the benefit held in those analyses, although the paper does not show that data.

Of 856 women who finished the core phase, 684 entered a 52-week open-label extension and 272 completed it. Improvements were sustained and no new safety signals appeared, but an open-label study has no placebo group and is made up of people who chose to continue, so it says more about safety than about efficacy.

Independent critics have been pointed. A 2024 analysis in the Journal of Sex Research, titled "Small Effects, Questionable Outcomes", argued that the chosen questionnaires have weak validity evidence in women with HSDD, that results for 8 of the 11 efficacy outcomes registered on ClinicalTrials.gov had gone unpublished, and that effects on those outcomes ranged from nil to small. A 2023 expert review reached a gentler version of the same conclusion: moderately safe and well tolerated, with an overall clinical benefit that appears modest. The expert review also acknowledges how hard sexual-desire trials are to run, given large placebo effects and outcomes that depend on recalling feelings over a month.

A sponsor-authored subgroup analysis of the 1,202 women in the efficacy population found the benefit was broadly consistent across age, weight, body mass index, and baseline testosterone levels, with few exceptions.

What about men? The evidence, stated plainly

PT-141 is widely marketed to men for erectile dysfunction and libido. As of September 2026, bremelanotide is not FDA approved for any use in men, and the approved product's label says so explicitly. Any prescribing for men is off-label. Here is the entire body of human evidence that a careful search turns up.

Several things stand out. The first three studies were run or funded by the developer, were early-phase, and measured erections in a lab over a few hours, not sexual function at home over months. The one large at-home trial comes from a single center, and the journal that published it has since issued an expression of concern, which means its reliability is in question. Treat its numbers with caution.

Doses matter too. The men's studies used several milligrams at a time (7.5 mg and 10 mg by nasal spray in two of them, 4 or 6 mg by injection in men with ED), against the 1.75 mg injection approved for women. Nasal and injected doses are not directly comparable milligram for milligram, but exposure could still be high: the label notes that blood levels after a 20 mg intranasal dose peak about 2.5 times higher than with the approved injection, and that nausea, skin darkening, and more pronounced blood pressure increases are more likely at higher doses. The phase 2b paper in women mentions that intensive blood pressure monitoring was built in to address FDA concerns raised after earlier studies of the intranasal formulation. As of September 2026, no nasal bremelanotide product has been FDA approved.

What is missing is the important part: no published phase 3 trial in men, no long-term safety data in men, and no label dose for men. In June 2024, Palatin announced a small open-label phase 2 study of about 50 men testing bremelanotide given together with a PDE5 inhibitor after PDE5 inhibitors alone had failed. As of this writing, no peer-reviewed results from that study could be found. The biology makes a central erection-initiating effect plausible. Plausible and proven are different, and men deserve to be told which one they are buying.

What to expect: onset, duration, and side effects

Timing

Blood levels peak about an hour after injection, and the label's minimum lead time is 45 minutes. Beyond that the label is candid that the optimal window is not known and that you and your prescriber may need to find it by experience, balancing effect against nausea. Trial benefits on the monthly questionnaires showed up by week 4. The label's 8-week stopping rule gives a reasonable frame: if nothing has changed after 8 weeks of use, the label says to discontinue.

Common side effects and how often they happened

These frequencies come from the pooled phase 3 trials (627 women on bremelanotide, 620 on placebo) as reported on the label.

Nausea is the defining side effect. Per the label it typically began within an hour of the dose and lasted about two hours. It was worst with the first dose, when 21% of women reported it, and fell to about 3% after later doses. Thirteen percent of women took an anti-nausea medicine. The label also warns that bremelanotide may slow stomach emptying, which can delay absorption of medicines taken by mouth.

The blood pressure effect

Every dose transiently raises blood pressure and slows heart rate. In clinical studies the maximum increases were 6 mmHg systolic (the top number) and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate falling by up to 5 beats per minute. Values usually returned to baseline within 12 hours. For a healthy person that is a small, brief change. For someone with heart disease it is an unnecessary strain, which is why the label contraindicates the drug in people with uncontrolled hypertension or known cardiovascular disease and does not recommend it for people at high cardiovascular risk.

Skin darkening

Because bremelanotide activates MC1R on pigment cells, it can cause focal hyperpigmentation: darkened patches, including on the face, gums, and breasts. This occurred in 1% of women using up to 8 doses a month in the phase 3 trials and in none on placebo. With daily dosing for 8 days in a separate study, 38% developed it. People with darker skin were more likely to be affected, and the label notes that the darkening did not resolve in every case after stopping. This is the main reason for the 8-dose monthly ceiling, and a strong reason to be wary of any protocol that calls for frequent or daily use.

The sibling guide on PT-141 side effects and safety covers the full risk picture, including the naltrexone interaction, pregnancy, and the single case of acute hepatitis reported in the extension study.

When to seek urgent care

Get emergency help for chest pain or pressure, shortness of breath, fainting, a sudden severe headache, weakness or numbness on one side, or signs of a serious allergic reaction such as swelling of the face or throat or trouble breathing. Contact your prescriber promptly for vomiting that will not stop, new or spreading dark patches of skin, yellowing of the skin or eyes, or a positive pregnancy test. Men should treat an erection lasting more than 4 hours as an emergency, as with any erection-related medicine.

Who it is for, and who should not use it

The trials tell you who the evidence applies to: healthy premenopausal women, average age 39, in stable relationships, with at least 6 months of distressing low desire after a period of normal desire, and without depression or other psychiatric conditions needing medication. Women taking antidepressants, mood stabilizers, or benzodiazepines were excluded, so the drug is untested in a group where low desire is especially common.

Based on the label, bremelanotide is contraindicated or discouraged in these situations:

• Uncontrolled high blood pressure or known cardiovascular disease (contraindicated), and high cardiovascular risk (not recommended).
• Pregnancy. Animal studies suggest potential fetal harm. The label advises effective contraception during use and stopping if pregnancy is suspected.
• Taking oral naltrexone for alcohol or opioid dependence. Bremelanotide may significantly lower naltrexone levels, and the label says to avoid the combination.
• Severe kidney or liver impairment. Drug exposure roughly doubles in severe kidney impairment, and the label advises caution because side effects may be more frequent and more severe.
• Groups outside the approval trials: postmenopausal women, men, anyone under 18, and adults 65 and older.

Low desire also has causes that no peptide addresses. The approved indication itself names three that must be ruled out first: another medical or psychiatric condition, problems in the relationship, and the effects of a medication or other substance.

Non-approved and off-label PT-141, stated plainly

PT-141 offered through wellness and peptide therapy channels is often not the approved autoinjector. It can be bremelanotide prepared by a compounding pharmacy, or supplied by a peptide company and reconstituted in a clinic, offered as a vial, a nasal spray, or another form, and marketed to men as well as women. No reliable data describe how much is sold or in which forms. Three facts help you judge what you are being offered.

1. PT-141 that is not the approved product, whether from a compounding pharmacy or a peptide supplier, is not FDA approved. In the FDA's own words, the agency does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed, and peptides sold by suppliers have not been through FDA review at all. The FDA warns that poor compounding practices can lead to contamination or to products with too much or too little active ingredient.
2. Compounding appears to be permitted within limits, but the FDA has not said so about bremelanotide specifically. This point applies to the compounding route only. Under section 503A of federal law, a licensed pharmacy may compound with a bulk substance that is a component of an FDA-approved drug, for an individual patient with a valid prescription. Bremelanotide is the active ingredient of an approved drug, so it appears to fit that general rule. That is a reading of the FDA's general framework, not an FDA statement about this drug. Pharmacies also may not regularly make what the FDA calls essentially a copy of a commercially available drug. FDA guidance treats a compounded product with the same active ingredient, a similar strength, and the same route as a copy unless the prescriber determines that a change makes a significant difference for that specific patient. As of September 2026, bremelanotide does not appear on the FDA's page of bulk substances that may present significant safety risks, while Melanotan II is discussed there.
3. The evidence does not transfer automatically. The trial data and the label apply to a 1.75 mg subcutaneous dose in premenopausal women. Different doses, nasal sprays, oral forms, daily schedules, and use in men or postmenopausal women are all outside what was tested for approval. For those uses there are no phase 3 data on benefit and no systematic data on risk.

Rx2BFIT does not dispense the approved autoinjector. Its PT-141 comes from a supplier whose batches are tested by an independent laboratory for identity and purity, with a certificate of analysis on file, and is reconstituted in the office under Dr. Patel's supervision. It is not an FDA-approved medication, and that, along with the known risks, is reviewed with every patient before starting.

Products sold online as "research chemicals" or "not for human use" are a separate and riskier category. They are not prescription medicines at all, and no regulator has verified what is in the vial. The PT-141 treatment overview describes how the prescription form is used under medical supervision.

Myths versus realities

Myth: PT-141 is "female Viagra"

Reality: the mechanisms have nothing in common. Sildenafil boosts a blood-flow pathway in the genitals and does nothing without stimulation. Bremelanotide acts on brain receptors tied to desire, and in a lab study it did not measurably change vaginal blood flow.

Myth: it is an aphrodisiac that works on anyone

Reality: it was tested in women with a diagnosed desire disorder, and even there about 36% of women on placebo reported benefit and the average drug effect over placebo was small to moderate. The label specifically says it is not indicated to enhance sexual performance. There are no good data in people with normal desire.

Myth: it is FDA approved, so any PT-141 is FDA approved

Reality: only the 1.75 mg autoinjector is FDA approved, and only for one group of patients. Vials, nasal sprays, and troches from compounding pharmacies or peptide suppliers have not been reviewed by the FDA for safety, effectiveness, or quality.

Myth: it is proven for men

Reality: the support consists of early-phase studies at higher doses, mostly with a discontinued nasal spray, plus one larger trial that now carries an expression of concern. No phase 3 trial in men has been published.

Myth: more frequent dosing means better results

Reality: no evidence supports that, and the risks climb. Daily dosing produced skin darkening in 38% of participants within 8 days in one study, and each dose adds hours of elevated blood pressure. The label caps use at one dose per 24 hours and recommends no more than 8 per month.

Questions to ask your prescriber

• Does my situation match acquired, generalized HSDD, or could a medication, a health condition, mood, pain, or relationship factors explain my low desire?
• Is what you are prescribing the FDA-approved autoinjector or a non-approved product? If it is not the approved product, where does it come from, is each batch tested by an independent laboratory for identity and purity, can I see the certificate of analysis, and why is that version appropriate for me?
• Is this use on-label or off-label for someone like me, and what evidence supports the dose and route you are suggesting?
• Has my blood pressure been checked recently, and do I have any cardiovascular risk factors that change the picture?
• What is the plan for nausea, and should it change how I time the dose?
• How will I judge whether it is working, and when do I stop if it is not? The label uses 8 weeks.
• Do any of my oral medicines depend on fast or complete absorption, and do I take naltrexone?
• What contraception should I use while taking it?

Sexual desire sits at the intersection of hormones, mood, relationships, sleep, and health. A broader look at healthy aging and wellness factors often matters as much as any single medication, and a good prescriber will look at those first.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.